S&P 500   4,686.75
DOW   35,719.43
QQQ   397.83
S&P 500   4,686.75
DOW   35,719.43
QQQ   397.83
S&P 500   4,686.75
DOW   35,719.43
QQQ   397.83
S&P 500   4,686.75
DOW   35,719.43
QQQ   397.83
NASDAQ:ITMR

Itamar Medical Stock Competitors

$30.65
-0.02 (-0.07%)
(As of 12/7/2021 12:00 AM ET)
Add
Compare
Today's Range
$30.54
$30.80
50-Day Range
$30.20
$30.67
52-Week Range
$16.36
$30.80
Volume
36,092 shs
Average Volume
82,759 shs
Market Capitalization
$493.71 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.73

Itamar Medical (NASDAQ:ITMR) Vs. USNA, TRIL, GBT, SAVA, LNTH, HSKA, IRWD, NSTG, VCEL, and MORF

Should you be buying Itamar Medical stock or one of its competitors? The main competitors of Itamar Medical include USANA Health Sciences (USNA), Trillium Therapeutics (TRIL), Global Blood Therapeutics (GBT), Cassava Sciences (SAVA), Lantheus (LNTH), Heska (HSKA), Ironwood Pharmaceuticals (IRWD), NanoString Technologies (NSTG), Vericel (VCEL), and Morphic (MORF). These companies are all part of the "medical" sector.

Itamar Medical vs.

Trillium Therapeutics (NASDAQ:TRIL) and Itamar Medical (NASDAQ:ITMR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, media sentiment, analyst recommendations, community ranking, earnings, valuation and risk.

Trillium Therapeutics received 269 more outperform votes than Itamar Medical when rated by MarketBeat users. Likewise, 72.94% of users gave Trillium Therapeutics an outperform vote while only 60.29% of users gave Itamar Medical an outperform vote.

CompanyUnderperformOutperform
Trillium TherapeuticsOutperform Votes
310
72.94%
Underperform Votes
115
27.06%
Itamar MedicalOutperform Votes
41
60.29%
Underperform Votes
27
39.71%

Trillium Therapeutics currently has a consensus target price of $20.30, indicating a potential upside of 10.09%. Itamar Medical has a consensus target price of $31.37, indicating a potential upside of 2.35%. Given Trillium Therapeutics' higher possible upside, equities analysts plainly believe Trillium Therapeutics is more favorable than Itamar Medical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Trillium Therapeutics
0 Sell rating(s)
5 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.17
Itamar Medical
0 Sell rating(s)
5 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.17

Trillium Therapeutics has a beta of 2.08, indicating that its share price is 108% more volatile than the S&P 500. Comparatively, Itamar Medical has a beta of 0.73, indicating that its share price is 27% less volatile than the S&P 500.

Itamar Medical has higher revenue and earnings than Trillium Therapeutics. Itamar Medical is trading at a lower price-to-earnings ratio than Trillium Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trillium Therapeutics$150 thousand12,907.39-$59.35 million$0.6229.74
Itamar Medical$41.03 million12.03-$21.75 million-$1.35-22.70

Itamar Medical's return on equity of 0.00% beat Trillium Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Trillium Therapeutics N/A -23.31% -18.66%
Itamar Medical N/A N/A N/A

In the previous week, Itamar Medical had 2 more articles in the media than Trillium Therapeutics. MarketBeat recorded 2 mentions for Itamar Medical and 0 mentions for Trillium Therapeutics. Itamar Medical's average media sentiment score of 0.49 beat Trillium Therapeutics' score of 0.00 indicating that Itamar Medical is being referred to more favorably in the news media.

Company Overall Sentiment
Trillium Therapeutics Neutral
Itamar Medical Neutral

87.2% of Trillium Therapeutics shares are held by institutional investors. Comparatively, 42.2% of Itamar Medical shares are held by institutional investors. 9.1% of Trillium Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Trillium Therapeutics beats Itamar Medical on 9 of the 15 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ITMR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment >-1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

Itamar Medical (NASDAQ:ITMR) vs. Its Competitors

TypeItamar Medical IndustryMedical SectorNASDAQ Exchange
Market Cap$493.71M$2.52B$4.96B$7.91B
Dividend YieldN/A1.90%2.05%2.56%
P/E Ratio-22.700.7222.3123.43
Price / Sales12.03646.592,429.35276.02
Price / CashN/A124.2061.88204.50
Price / BookN/A1.846.156.53
Net IncomeN/A$647.54M$96.04M$154.44M
7 Day Performance0.26%35.45%0.98%2.05%
1 Month Performance0.43%-2.71%-12.06%-9.37%
1 Year Performance57.18%62.63%9.29%26.38%

Itamar Medical Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
USNA
USANA Health Sciences
2.2848 of 5 stars
$100.55
-0.5%
$124.00
-23.3%
+30.4%$1.96B$1.13B15.351,943Positive News
TRIL
Trillium Therapeutics
1.7098 of 5 stars
$18.44
-0.0%
$20.30
-10.1%
+20.4%$1.94B$150K29.7433
GBT
Global Blood Therapeutics
1.965 of 5 stars
$29.62
-4.9%
$63.31
-113.7%
-28.4%$1.91B$123.80M-6.64389Analyst Upgrade
News Coverage
Gap Up
SAVA
Cassava Sciences
1.7064 of 5 stars
$47.65
-7.7%
$146.00
-206.4%
+530.3%$1.91BN/A-86.6311Gap Up
LNTH
Lantheus
2.0048 of 5 stars
$27.84
-4.3%
$27.00
-3.0%
+102.0%$1.88B$339.41M-54.59595
HSKA
Heska
2.7448 of 5 stars
$175.71
-7.1%
$250.83
-42.8%
+34.6%$1.88B$197.32M924.84602
IRWD
Ironwood Pharmaceuticals
2.2831 of 5 stars
$11.44
-2.2%
$14.50
-26.7%
-2.7%$1.87B$389.52M3.52232
NSTG
NanoString Technologies
1.8731 of 5 stars
$40.73
-6.6%
$67.50
-65.7%
-35.7%$1.86B$117.32M-16.69579
VCEL
Vericel
1.8548 of 5 stars
$39.71
-5.6%
$53.00
-33.5%
+55.7%$1.86B$124.18M-3,971.00273
MORF
Morphic
2.3598 of 5 stars
$49.47
-3.5%
$85.00
-71.8%
+56.1%$1.83B$44.94M-18.6089
SRNE
Sorrento Therapeutics
1.9917 of 5 stars
$5.95
-11.8%
$28.67
-381.8%
-22.6%$1.82B$39.99M-4.84502
CLDX
Celldex Therapeutics
2.2 of 5 stars
$38.77
-6.1%
$59.00
-52.2%
+107.3%$1.81B$7.42M-22.03124
ATAI
Atai Life Sciences
2.106 of 5 stars
$11.18
-5.4%
$29.54
-164.2%
N/A$1.79BN/A0.0035
SHCR
Sharecare
1.7 of 5 stars
$5.28
-2.1%
$13.50
-155.7%
N/A$1.79BN/A0.002,021
CCCC
C4 Therapeutics
2.3579 of 5 stars
$36.78
-3.1%
$48.50
-31.9%
+11.1%$1.79B$33.19M0.0099
ALEC
Alector
2.6214 of 5 stars
$21.94
-9.6%
$40.33
-83.8%
+55.7%$1.78B$21.10M-42.19171Gap Up
AGIO
Agios Pharmaceuticals
1.8164 of 5 stars
$32.69
-0.1%
$61.50
-88.1%
-25.3%$1.78B$203.20M1.45562High Trading Volume
TVTX
Travere Therapeutics
1.5831 of 5 stars
$28.75
-3.4%
$32.17
-11.9%
+11.3%$1.76B$198.32M-6.30262
CDMO
Avid Bioservices
2.0814 of 5 stars
$28.50
-1.1%
$28.00
-1.8%
+164.4%$1.75B$95.87M356.29255News Coverage
Gap Up
DVAX
Dynavax Technologies
2.5881 of 5 stars
$14.45
-7.3%
$21.00
-45.3%
+204.2%$1.73B$46.55M-41.29245Analyst Revision
Gap Up
VERV
Verve Therapeutics
2.1531 of 5 stars
$35.74
-10.0%
$71.20
-99.2%
N/A$1.72BN/A0.0063Insider Buying
News Coverage
Gap Up
KDMN
Kadmon
1.3048 of 5 stars
$9.50
-0.0%
$11.25
-18.4%
+126.2%$1.70B$8.29M-13.19127
HLTH
Cue Health
0 of 5 stars
$11.55
-7.2%
N/AN/A$1.69BN/A0.001,254
CRON
Cronos Group
1.6431 of 5 stars
$4.51
-4.2%
$8.17
-81.1%
-46.8%$1.69B$46.72M-11.00665Upcoming Earnings
ERAS
Erasca
1.4715 of 5 stars
$13.91
-10.1%
$26.50
-90.5%
N/A$1.69BN/A0.002,021Gap Up
IGMS
IGM Biosciences
2.2198 of 5 stars
$51.87
-3.4%
$101.00
-94.7%
-28.9%$1.68BN/A-12.29107News Coverage
Positive News
MLAB
Mesa Laboratories
1.8648 of 5 stars
$321.67
-1.6%
N/A+19.6%$1.68B$133.94M345.89506Insider Selling
News Coverage
ISEE
IVERIC bio
2.3181 of 5 stars
$14.47
-4.4%
$22.00
-52.0%
+113.1%$1.66BN/A-13.0457
SUPN
Supernus Pharmaceuticals
2.5198 of 5 stars
$30.97
-2.9%
$39.50
-27.5%
+44.0%$1.64B$520.40M20.51563
ESTA
Establishment Labs
2.4915 of 5 stars
$68.20
-6.1%
$85.60
-25.5%
+127.0%$1.64B$84.68M-50.52521
PTGX
Protagonist Therapeutics
1.7265 of 5 stars
$33.82
-3.0%
$58.00
-71.5%
+47.6%$1.61B$28.63M-14.0379Gap Up
RCKT
Rocket Pharmaceuticals
2.3431 of 5 stars
$25.00
-7.8%
$73.14
-192.6%
-24.9%$1.61BN/A-8.14101News Coverage
Gap Up
AMWL
American Well
2.3198 of 5 stars
$6.59
-4.6%
$14.00
-112.4%
-77.3%$1.60B$245.26M0.00812Analyst Revision
CYH
Community Health Systems
1.9909 of 5 stars
$12.01
-1.2%
$14.50
-20.8%
+39.2%$1.59B$11.79B4.0770,000Gap Up
ATRA
Atara Biotherapeutics
1.8121 of 5 stars
$17.89
-5.1%
$30.33
-69.6%
-31.8%$1.58BN/A-4.94437
KRYS
Krystal Biotech
2.2464 of 5 stars
$71.03
-4.9%
$115.33
-62.4%
+25.8%$1.58BN/A-26.2175Gap Up
High Trading Volume
ENTA
Enanta Pharmaceuticals
2.2681 of 5 stars
$77.66
-3.3%
$90.88
-17.0%
+82.2%$1.58B$97.07M-19.86141
SEER
Seer
1.9899 of 5 stars
$25.17
-11.8%
$64.67
-156.9%
-58.7%$1.55B$660K-18.2460Gap Up
INBX
Inhibrx
2.1331 of 5 stars
$40.45
-9.6%
$53.00
-31.0%
+14.3%$1.54B$12.89M-19.5488
QTRX
Quanterix
2.1265 of 5 stars
$41.88
-7.7%
$66.00
-57.6%
-11.5%$1.53B$86.38M-30.79314Gap Up
BCYC
Bicycle Therapeutics
2.4048 of 5 stars
$52.02
-3.2%
$68.25
-31.2%
+170.7%$1.53B$10.39M-18.002,020
SILK
Silk Road Medical
1.9615 of 5 stars
$43.66
-2.2%
$57.75
-32.3%
-26.3%$1.52B$75.23M-28.91281Gap Up
NFH
New Frontier Health
1.2048 of 5 stars
$11.45
-0.5%
$12.00
-4.8%
+28.8%$1.51B$346.44M-26.633,309
MYOV
Myovant Sciences
1.9881 of 5 stars
$16.16
-6.6%
$25.40
-57.2%
-31.3%$1.51B$59.32M-6.19407News Coverage
RDNT
RadNet
1.9981 of 5 stars
$28.35
-0.0%
$35.00
-23.5%
+47.6%$1.51B$1.07B44.308,327Insider Selling
AVNS
Avanos Medical
2.4148 of 5 stars
$30.94
-0.6%
$44.33
-43.3%
-33.0%$1.49B$714.80M-28.135,380News Coverage
High Trading Volume
BLFS
BioLife Solutions
2.2438 of 5 stars
$36.45
-3.6%
$59.86
-64.2%
-8.6%$1.48B$48.09M364.54196
ADCT
ADC Therapeutics
1.9917 of 5 stars
$21.33
-6.0%
$45.20
-111.9%
-38.5%$1.47B$2.34M-6.50208
ADUS
Addus HomeCare
2.3298 of 5 stars
$92.19
-2.9%
$119.50
-29.6%
-12.8%$1.47B$764.78M36.5835,139
AMRN
Amarin
1.785 of 5 stars
$3.69
-3.3%
$11.20
-203.5%
-27.4%$1.46B$614.06M89.252,020
This page was last updated on 12/8/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.